Records
Browse every document routed through Assort Design.
Route Filters
FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA Skip to main content Skip to FDA Search Skip to in this section menu Skip to footer links An official web
One-line summary: The FDA has approved Rezdiffra (resmetirom), the first drug to treat adults with noncirrhotic NASH and moderate to advanced liver fibrosis, based on surrogate endpoint improvement at 12 months alongside diet and exercise.
Citations: 5 · Risk: 0 High / 0 Medium / 0 Low
Liver failure: Stages, treatment options, outlook, and more Medical News Today Health Conditions Health Conditions Alzheimer's & Dementia Anxiety Asthma & Allergies Atopic Dermatitis Breast Cancer Can
One-line summary: Liver failure progresses through stages from inflammation to end-stage liver disease, requiring timely diagnosis and treatment to improve outcomes and may ultimately necessitate transplant for survival.
Citations: 2 · Risk: 0 High / 0 Medium / 0 Low
Biological aging: Can a daily multivitamin help 'turn back the clock'? Medical News Today Health Conditions Health Conditions Alzheimer's & Dementia Anxiety Asthma & Allergies Atopic Dermatitis Breast
One-line summary: A large randomized clinical trial (COSMOS) suggests that daily multivitamin use modestly slows biological aging in older adults, especially those with accelerated aging, though further research is needed.
Citations: 3 · Risk: 0 High / 1 Medium / 0 Low
New insights into macrophages' role in MASH and liver fibrosis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News He
One-line summary: TREM2-expressing lipid-associated macrophages are critical for resolving MASH and liver fibrosis by promoting scar tissue degradation and anti-inflammatory responses.
Citations: 3 · Risk: 1 High / 0 Medium / 0 Low
New study helps better understand the pathology of fatty liver disease MASH Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional
One-line summary: A recent study reveals that antigen-driven clonal expansion of CD8+ T cells plays a key role in MASH pathogenesis, offering insights for early diagnosis and intervention.
Citations: 5 · Risk: 1 High / 1 Medium / 0 Low
Two new subtypes of MASH revealed with different risks and outcomes Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food Ne
One-line summary: A landmark study identifies two distinct MASH subtypes with differing risks and outcomes, underscoring the need for subtype-specific diagnosis and treatment.
Citations: 5 · Risk: 1 High / 0 Medium / 0 Low
CePA: Novel nanomedicine for alleviating MASH via mTOR repression Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News
One-line summary: CePA, a cerium-phytic acid nanomedicine, alleviates metabolic dysfunction-associated steatohepatitis (MASH) by repressing mTOR phosphorylation, reducing hepatic lipogenesis, inflammation, and fibrosis in preclinical models.
Citations: 4 · Risk: 1 High / 0 Medium / 0 Low
Scientists reveal why non-alcoholic steatohepatitis worsens in obese people Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional
One-line summary: Saturated fat increases sphingosine-1-phosphate (S1P) levels in obese individuals, driving inflammation and progression of non-alcoholic steatohepatitis (NASH), unlike unsaturated fat.
Citations: 4 · Risk: 2 High / 0 Medium / 0 Low
A new, potential treatment for nonalcoholic steatohepatitis with fibrosis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional F
One-line summary: A novel therapeutic approach inducing cytoglobin (CYGB) in hepatic stellate cells shows promise for treating nonalcoholic steatohepatitis (NASH) with fibrosis by mitigating oxidative DNA damage.
Citations: 4 · Risk: 1 High / 0 Medium / 0 Low
Potential leptin therapy for nonalcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health
One-line summary: Leptin therapy using metreleptin shows promise in reducing liver fat and improving nonalcoholic steatohepatitis (NASH) in patients with low leptin levels, including those with partial lipodystrophy.
Citations: 4 · Risk: 1 High / 0 Medium / 0 Low